Lynn Hassman
Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Uveitis | 5 | 2024 | 127 | 1.400 |
Why?
| Optic Disk | 1 | 2024 | 40 | 0.860 |
Why?
| Papilledema | 1 | 2024 | 40 | 0.850 |
Why?
| Retinal Diseases | 1 | 2021 | 86 | 0.710 |
Why?
| Eye Diseases | 1 | 2021 | 79 | 0.670 |
Why?
| Metagenome | 1 | 2021 | 137 | 0.670 |
Why?
| Metagenomics | 1 | 2021 | 154 | 0.650 |
Why?
| Panophthalmitis | 1 | 2018 | 2 | 0.630 |
Why?
| Eye Infections, Viral | 1 | 2018 | 6 | 0.630 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2021 | 250 | 0.620 |
Why?
| Vitreous Body | 1 | 2018 | 105 | 0.580 |
Why?
| Herpes Simplex | 1 | 2018 | 93 | 0.580 |
Why?
| Herpesvirus 1, Human | 1 | 2018 | 85 | 0.570 |
Why?
| Herpesvirus 8, Human | 2 | 2012 | 59 | 0.380 |
Why?
| Palatine Tonsil | 1 | 2011 | 44 | 0.350 |
Why?
| Plasma Cells | 1 | 2011 | 65 | 0.350 |
Why?
| Uveitis, Anterior | 2 | 2024 | 13 | 0.280 |
Why?
| B-Lymphocytes | 1 | 2011 | 823 | 0.240 |
Why?
| Receptors, CCR6 | 1 | 2024 | 4 | 0.230 |
Why?
| HLA-B27 Antigen | 1 | 2024 | 15 | 0.230 |
Why?
| Cell Proliferation | 1 | 2011 | 2347 | 0.210 |
Why?
| Cell Differentiation | 1 | 2011 | 1901 | 0.210 |
Why?
| Fluorescein Angiography | 1 | 2024 | 143 | 0.210 |
Why?
| HLA-B Antigens | 1 | 2022 | 62 | 0.200 |
Why?
| Tomography, Optical Coherence | 1 | 2024 | 187 | 0.200 |
Why?
| Interferon-gamma | 2 | 2021 | 762 | 0.190 |
Why?
| Vision, Ocular | 1 | 2021 | 33 | 0.190 |
Why?
| Scleritis | 1 | 2021 | 19 | 0.190 |
Why?
| Visual Acuity | 1 | 2024 | 322 | 0.190 |
Why?
| Central Nervous System Diseases | 1 | 2022 | 67 | 0.180 |
Why?
| Macrophages, Peritoneal | 1 | 2021 | 90 | 0.180 |
Why?
| Eye Proteins | 1 | 2021 | 88 | 0.170 |
Why?
| Sarcoidosis | 1 | 2022 | 155 | 0.170 |
Why?
| Gene Expression | 2 | 2021 | 1462 | 0.150 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2022 | 703 | 0.150 |
Why?
| Diagnosis, Differential | 2 | 2020 | 1417 | 0.150 |
Why?
| Precision Medicine | 1 | 2021 | 384 | 0.140 |
Why?
| Transcriptome | 2 | 2021 | 883 | 0.140 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 485 | 0.140 |
Why?
| Inflammatory Bowel Diseases | 1 | 2021 | 312 | 0.140 |
Why?
| Peptides | 1 | 2022 | 911 | 0.140 |
Why?
| Autoimmunity | 1 | 2022 | 860 | 0.130 |
Why?
| Computational Biology | 1 | 2021 | 598 | 0.130 |
Why?
| Chemokines, CC | 2 | 2006 | 32 | 0.130 |
Why?
| Disease Models, Animal | 3 | 2024 | 3953 | 0.130 |
Why?
| Humans | 13 | 2024 | 129116 | 0.130 |
Why?
| Ultrasonography | 1 | 2018 | 724 | 0.120 |
Why?
| MicroRNAs | 1 | 2021 | 677 | 0.120 |
Why?
| RNA | 1 | 2021 | 883 | 0.110 |
Why?
| Macrophages | 1 | 2021 | 1466 | 0.110 |
Why?
| Algorithms | 1 | 2020 | 1621 | 0.100 |
Why?
| CD8-Positive T-Lymphocytes | 3 | 2024 | 847 | 0.100 |
Why?
| Gene Expression Regulation | 2 | 2021 | 2508 | 0.100 |
Why?
| Poly(A)-Binding Protein I | 1 | 2012 | 1 | 0.100 |
Why?
| RNA, Nuclear | 1 | 2012 | 4 | 0.100 |
Why?
| Adult | 4 | 2024 | 35510 | 0.100 |
Why?
| Cytoplasm | 1 | 2012 | 258 | 0.090 |
Why?
| Lymphoma, Primary Effusion | 1 | 2011 | 3 | 0.090 |
Why?
| Castleman Disease | 1 | 2011 | 12 | 0.090 |
Why?
| Aging | 1 | 2021 | 1771 | 0.090 |
Why?
| Disease Transmission, Infectious | 1 | 2011 | 57 | 0.090 |
Why?
| RNA, Messenger | 2 | 2021 | 2676 | 0.080 |
Why?
| Antigens, Viral | 1 | 2011 | 174 | 0.080 |
Why?
| Genome, Viral | 1 | 2011 | 127 | 0.080 |
Why?
| Viral Proteins | 1 | 2012 | 321 | 0.080 |
Why?
| Cell Nucleus | 1 | 2012 | 579 | 0.080 |
Why?
| Female | 5 | 2024 | 68510 | 0.080 |
Why?
| Tomography, X-Ray Computed | 1 | 2018 | 2541 | 0.080 |
Why?
| RNA, Viral | 1 | 2012 | 617 | 0.080 |
Why?
| Middle Aged | 3 | 2024 | 31074 | 0.070 |
Why?
| Young Adult | 1 | 2024 | 12389 | 0.070 |
Why?
| Receptors, Chemokine | 1 | 2006 | 45 | 0.070 |
Why?
| Retrospective Studies | 1 | 2024 | 14571 | 0.070 |
Why?
| Bronchial Hyperreactivity | 1 | 2006 | 104 | 0.060 |
Why?
| Nuclear Proteins | 1 | 2011 | 660 | 0.060 |
Why?
| Flow Cytometry | 2 | 2024 | 1142 | 0.060 |
Why?
| Interleukin-13 | 1 | 2006 | 145 | 0.060 |
Why?
| Chemokines, CXC | 1 | 2004 | 68 | 0.060 |
Why?
| Adolescent | 1 | 2024 | 20301 | 0.060 |
Why?
| Aged | 1 | 2024 | 22083 | 0.060 |
Why?
| Aqueous Humor | 1 | 2024 | 33 | 0.060 |
Why?
| Eosinophils | 1 | 2006 | 324 | 0.060 |
Why?
| Integrins | 1 | 2024 | 92 | 0.050 |
Why?
| Cells, Cultured | 1 | 2011 | 4010 | 0.050 |
Why?
| Animals | 6 | 2024 | 34600 | 0.050 |
Why?
| Synovial Fluid | 1 | 2022 | 66 | 0.050 |
Why?
| Cross Reactions | 1 | 2022 | 128 | 0.050 |
Why?
| Male | 3 | 2024 | 63194 | 0.050 |
Why?
| Lung | 2 | 2006 | 3752 | 0.050 |
Why?
| Peptide Library | 1 | 2022 | 85 | 0.050 |
Why?
| Amino Acid Motifs | 1 | 2022 | 209 | 0.050 |
Why?
| Trans-Activators | 1 | 2004 | 381 | 0.050 |
Why?
| Mice, Knockout | 3 | 2021 | 2765 | 0.050 |
Why?
| Spondylitis, Ankylosing | 1 | 2022 | 46 | 0.050 |
Why?
| Thioglycolates | 1 | 2021 | 3 | 0.050 |
Why?
| Gene Expression Profiling | 3 | 2021 | 1689 | 0.050 |
Why?
| Macrophage Activation | 1 | 2021 | 187 | 0.040 |
Why?
| Cellular Senescence | 1 | 2021 | 174 | 0.040 |
Why?
| Chronic Disease | 2 | 2021 | 1706 | 0.040 |
Why?
| Genetic Markers | 1 | 2021 | 339 | 0.040 |
Why?
| Autoantigens | 1 | 2022 | 416 | 0.040 |
Why?
| Transcription, Genetic | 1 | 2006 | 1403 | 0.040 |
Why?
| Lung Diseases | 1 | 2006 | 723 | 0.040 |
Why?
| Sequence Analysis, RNA | 1 | 2021 | 428 | 0.040 |
Why?
| Single-Cell Analysis | 1 | 2021 | 274 | 0.040 |
Why?
| Gene Regulatory Networks | 1 | 2021 | 281 | 0.040 |
Why?
| DNA-Binding Proteins | 1 | 2004 | 1423 | 0.030 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2022 | 1048 | 0.030 |
Why?
| Mitochondria | 1 | 2021 | 854 | 0.030 |
Why?
| Inflammation | 2 | 2021 | 2668 | 0.030 |
Why?
| Mice | 4 | 2021 | 16644 | 0.030 |
Why?
| Case-Control Studies | 1 | 2020 | 3342 | 0.030 |
Why?
| Allergens | 2 | 2006 | 383 | 0.030 |
Why?
| Subcellular Fractions | 1 | 2012 | 80 | 0.020 |
Why?
| In Situ Hybridization | 1 | 2012 | 292 | 0.020 |
Why?
| Fluorescent Antibody Technique | 1 | 2012 | 374 | 0.020 |
Why?
| Asthma | 1 | 2004 | 2219 | 0.020 |
Why?
| Herpesviridae Infections | 1 | 2012 | 134 | 0.020 |
Why?
| Mice, Inbred C57BL | 1 | 2021 | 5284 | 0.020 |
Why?
| RNA, Untranslated | 1 | 2012 | 114 | 0.020 |
Why?
| Protein Transport | 1 | 2012 | 422 | 0.020 |
Why?
| Virus Replication | 1 | 2012 | 444 | 0.020 |
Why?
| Biomarkers | 1 | 2020 | 3896 | 0.020 |
Why?
| Cytokines | 2 | 2006 | 1987 | 0.020 |
Why?
| Receptors, CCR3 | 1 | 2006 | 8 | 0.020 |
Why?
| Chemokine CCL11 | 1 | 2006 | 25 | 0.020 |
Why?
| Guanine Nucleotide Exchange Factors | 1 | 2006 | 63 | 0.020 |
Why?
| Cathepsins | 1 | 2006 | 24 | 0.020 |
Why?
| Receptors, Cytokine | 1 | 2006 | 35 | 0.020 |
Why?
| Doxycycline | 1 | 2006 | 55 | 0.020 |
Why?
| Mucus | 1 | 2006 | 75 | 0.020 |
Why?
| Mast Cells | 1 | 2006 | 142 | 0.020 |
Why?
| STAT6 Transcription Factor | 1 | 2004 | 24 | 0.010 |
Why?
| Chemokine CXCL9 | 1 | 2004 | 25 | 0.010 |
Why?
| Chemokine CXCL10 | 1 | 2004 | 34 | 0.010 |
Why?
| STAT1 Transcription Factor | 1 | 2004 | 70 | 0.010 |
Why?
| Ovalbumin | 1 | 2004 | 177 | 0.010 |
Why?
| Ligands | 1 | 2006 | 614 | 0.010 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 757 | 0.010 |
Why?
| Eosinophilia | 1 | 2006 | 205 | 0.010 |
Why?
| Down-Regulation | 1 | 2004 | 634 | 0.010 |
Why?
| Cell Movement | 1 | 2006 | 939 | 0.010 |
Why?
| Mice, Inbred BALB C | 1 | 2004 | 1230 | 0.010 |
Why?
| Up-Regulation | 1 | 2004 | 828 | 0.010 |
Why?
| Kinetics | 1 | 2004 | 1617 | 0.010 |
Why?
| Mice, Transgenic | 1 | 2006 | 2079 | 0.010 |
Why?
| Signal Transduction | 1 | 2004 | 4838 | 0.010 |
Why?
|
|
Hassman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|